长期使用别嘌醇降低痛风患者前列腺癌风险:一项基于人群的研究
该研究分析台湾全民健康保险数据库2000年1月至2012年12月的数据,纳入25 770例40至100岁、无前列腺癌病史且从未使用过别嘌醇的痛风患者,比较不同别嘌醇使用时长队列的新发前列腺癌风险。多变量Cox回归显示,别嘌醇使用超过365天队列的前列腺癌风险显著低于未使用别嘌醇队列(校正HR=0.64,95%CI=0.45-0.9,P=0.011),倾向评分校正后趋势一致(校正HR=0.66,95%CI=0.46-0.93,P=0.019)。作者认为,长期(超过1年)使用别嘌醇可能与痛风患者前列腺癌风险降低相关。
要点
- 别嘌醇使用超过365天队列前列腺癌风险低于未使用队列(校正HR=0.64,95%CI=0.45-0.9,P=0.011)。
- 倾向评分校正后趋势一致(校正HR=0.66,95%CI=0.46-0.93,P=0.019)。
- 作者认为长期(超过1年)别嘌醇使用可能与痛风患者前列腺癌风险降低相关。
核心结论
- 长期(超过1年)使用别嘌醇可能与痛风患者前列腺癌风险降低相关。
研究设计与样本
- 基于台湾全民健康保险数据库2000年1月至2012年12月数据的基于人群研究,纳入25 770例40至100岁痛风患者。
- 设4个别嘌醇使用队列(使用超过365天、181-365天、91-180天、31-90天)和1个未使用别嘌醇队列,研究终点为新发前列腺癌诊断。
- 采用多变量Cox比例风险回归和倾向评分校正Cox回归模型,在调整潜在混杂因素后估计别嘌醇治疗与前列腺癌风险的关联。
主要发现
- 多变量Cox回归显示,别嘌醇使用超过365天队列的前列腺癌风险显著低于未使用别嘌醇队列(校正HR=0.64,95%CI=0.45-0.9,P=0.011)。
- 倾向评分校正后趋势保持一致(校正HR=0.66,95%CI=0.46-0.93,P=0.019)。
关键数值与推荐
- 别嘌醇使用超过365天队列 vs 未使用别嘌醇队列:校正HR=0.64,95%CI=0.45-0.9,P=0.011。
- 倾向评分校正后:别嘌醇使用超过365天队列 vs 未使用别嘌醇队列,校正HR=0.66,95%CI=0.46-0.93,P=0.019。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical observations indicated an increased risk of developing prostate cancer in gout patients. Chronic inflammation is postulated to be one crucial mechanism for prostate carcinogenesis. Allopurinol, a widely used antigout agent, possesses potent anti-inflammation capacity. We elucidated whether allopurinol decreases the risk of prostate cancer in gout patients. METHODS: We analyzed data retrieved from Taiwan National Health Insurance Database between January 2000 and December 2012. Patients diagnosed with gout during the study period with no history of prostate cancer and who had never used allopurinol were selected. Four allopurinol use cohorts (that is, allopurinol use (>365 days), allopurinol use (181-365 days), allopurinol use (91-180 days) and allopurinol use (31-90 days)) and one cohort without using allopurinol (that is, allopurinol use (No)) were included. The study end point was the diagnosis of new-onset prostate cancer. Multivariable Cox proportional hazards regression and propensity score-adjusted Cox regression models were used to estimate the association between the risk of prostate cancer and allopurinol treatment in gout patients after adjusting for potential confounders. RESULTS: A total of 25 770 gout patients (aged between 40 and 100 years) were included. Multivariable Cox regression analyses revealed that the risk of developing prostate cancer in the allopurinol use (>365 days) cohort was significantly lower than the allopurinol use (No) cohort (adjusted hazard ratio (HR)=0.64, 95% confidence interval (CI)=0.45-0.9, P=0.011). After propensity score adjustment, the trend remained the same (adjusted HR=0.66, 95% CI=0.46-0.93, P=0.019). CONCLUSIONS: Long-term (more than 1 year) allopurinol use may associate with a decreased risk of prostate cancer in gout patients.
引用
- Shih HJ, Kao MC, Tsai PS, et al. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis. 2017. PMID: 28398294. doi:10.1038/pcan.2017.14
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。